Neil D. Avent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Neil D. Avent has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
T. E. Madgett
School of Biomedical and Healthcare Sciences Plymouth University Peninsula Schools of Medicine and Dentistry Plymouth UK
2 shared publicationsTracey E Madgett
School of Biomedical and Healthcare Sciences, Plymouth University, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK
2 shared publicationsTracey E. Madgett
2 shared publications- Tracey E. Madgett
Faculty of Health – Drake Circus University of Plymouth, School of Biomedical Sciences Plymouth UK
2 shared publications A Webb
School of Biomedical and Biological Sciences, University of Plymouth, Plymouth, Devon, UK
1 shared publicationA. J. Halawani
School of Biomedical and Healthcare Sciences Plymouth University Peninsula Schools of Medicine and Dentistry Plymouth UK
1 shared publication
Latest Publications
- Open Access
- 1 December 2023
- Published by AME Publishing Company in Annals of Blood
- Vol. 8, 36
RHD molecular analysis—from discovery to next generation sequencing
This review traces the evolution of RHD genotyping from the very early days of the discovery of Rh polypeptides in 1982, and the pioneering work of the late 1980s and early 1990s that made the whole approach of RH genotyping possible. This work is often overlooked in contemporary Rh literature with citations of reviews being used which often do not give the complete background story. We have attempted to rectify this here. This review focuses primarily on RHD genotyping, primarily because of space constraints not to include RHCE but also because RHD is of greater clinical significance. In Europe many countries offer routine non-invasive prenatal RHD screening to direct the use of prophylactic anti-D to mothers that require it- namely are carrying D-positive fetuses. The genotyping approach is empirical (and wisely so) and any potential variant identified in this process is treated as D-positive. In such cases although sometimes unnecessary administration of prophylactic anti-D may be given, it only reflects the situation that predated mass scale non-invasive testing, and many countries not offering RHD screening. The complexity of the RHD gene and the known plethora of D variants (partial, weak D-elute and multiple genetic mechanisms generating the D-negative phenotype) are explored but only inasmuch as the technology to detect them is discussed. By far the most powerful means of accurate RHD genotyping, so called gold standard testing is next-generation sequencing although our discussion is tempered by several caveats mainly involving the rapid bioinformatic determination of a D variant from its resultant sequence. We stress however that next generation sequencing (NGS) offers the substantial advantage over other conventional RHD genotyping strategies in that novel variants can be identified whereas other methods require that the variant has been previously described so as to direct sequence specific analysis.
- 1 December 2023
- Published by AME Publishing Company in Annals of Blood
- Vol. 8, 36
Open AccessRHD molecular analysis—from discovery to next generation sequencing
This review traces the evolution of RHD genotyping from the very early days of the discovery of Rh polypeptides in 1982, and the pioneering work of the late 1980s and early 1990s that made the whole approach of RH genotyping possible. This work is often overlooked in contemporary Rh literature with citations of reviews being used which often do not give the complete background story. We have attempted to rectify this here. This review focuses primarily on RHD genotyping, primarily because of space constraints not to include RHCE but also because RHD is of greater clinical significance. In Europe many countries offer routine non-invasive prenatal RHD screening to direct the use of prophylactic anti-D to mothers that require it- namely are carrying D-positive fetuses. The genotyping approach is empirical (and wisely so) and any potential variant identified in this process is treated as D-positive. In such cases although sometimes unnecessary administration of prophylactic anti-D may be given, it only reflects the situation that predated mass scale non-invasive testing, and many countries not offering RHD screening. The complexity of the RHD gene and the known plethora of D variants (partial, weak D-elute and multiple genetic mechanisms generating the D-negative phenotype) are explored but only inasmuch as the technology to detect them is discussed. By far the most powerful means of accurate RHD genotyping, so called gold standard testing is next-generation sequencing although our discussion is tempered by several caveats mainly involving the rapid bioinformatic determination of a D variant from its resultant sequence. We stress however that next generation sequencing (NGS) offers the substantial advantage over other conventional RHD genotyping strategies in that novel variants can be identified whereas other methods require that the variant has been previously described so as to direct sequence specific analysis.
- Open Access
- 1 November 2015
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 61 (11) , 1399-1407
Fetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity than Real-time PCR
BACKGROUND: Noninvasive genotyping of fetal RHD (Rh blood group, D antigen) can prevent the unnecessary administration of prophylactic anti-D to women carrying RHD-negative fetuses. We evaluated laboratory methods for such genotyping. METHODS: Blood samples were collected in EDTA tubes and Streck® Cell-Free DNA™ blood collection tubes (Streck BCTs) from RHD-negative women (n = 46). Using Y-specific and RHD-specific targets, we investigated variation in the cell-free fetal DNA (cffDNA) fraction and determined the sensitivity achieved for optimal and suboptimal samples with a novel Droplet Digital™ PCR (ddPCR) platform compared with real-time quantitative PCR (qPCR). RESULTS: The cffDNA fraction was significantly larger for samples collected in Streck BCTs compared with samples collected in EDTA tubes (P < 0.001). In samples expressing optimal cffDNA fractions (≥4%), both qPCR and digital PCR (dPCR) showed 100% sensitivity for the TSPY1 (testis-specific protein, Y-linked 1) and RHD7 (RHD exon 7) assays. Although dPCR also had 100% sensitivity for RHD5 (RHD exon 5), qPCR had reduced sensitivity (83%) for this target. For samples expressing suboptimal cffDNA fractions (<2%), dPCR achieved 100% sensitivity for all assays, whereas qPCR achieved 100% sensitivity only for the TSPY1 (multicopy target) assay. CONCLUSIONS: qPCR was not found to be an effective tool for RHD genotyping in suboptimal samples (<2% cffDNA). However, when testing the same suboptimal samples on the same day by dPCR, 100% sensitivity was achieved for both fetal sex determination and RHD genotyping. Use of dPCR for identification of fetal specific markers can reduce the occurrence of false-negative and inconclusive results, particularly when samples express high levels of background maternal cell-free DNA.
- 1 November 2015
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 61 (11) , 1399-1407
Open AccessFetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity than Real-time PCR
BACKGROUND: Noninvasive genotyping of fetal RHD (Rh blood group, D antigen) can prevent the unnecessary administration of prophylactic anti-D to women carrying RHD-negative fetuses. We evaluated laboratory methods for such genotyping. METHODS: Blood samples were collected in EDTA tubes and Streck® Cell-Free DNA™ blood collection tubes (Streck BCTs) from RHD-negative women (n = 46). Using Y-specific and RHD-specific targets, we investigated variation in the cell-free fetal DNA (cffDNA) fraction and determined the sensitivity achieved for optimal and suboptimal samples with a novel Droplet Digital™ PCR (ddPCR) platform compared with real-time quantitative PCR (qPCR). RESULTS: The cffDNA fraction was significantly larger for samples collected in Streck BCTs compared with samples collected in EDTA tubes (P < 0.001). In samples expressing optimal cffDNA fractions (≥4%), both qPCR and digital PCR (dPCR) showed 100% sensitivity for the TSPY1 (testis-specific protein, Y-linked 1) and RHD7 (RHD exon 7) assays. Although dPCR also had 100% sensitivity for RHD5 (RHD exon 5), qPCR had reduced sensitivity (83%) for this target. For samples expressing suboptimal cffDNA fractions (<2%), dPCR achieved 100% sensitivity for all assays, whereas qPCR achieved 100% sensitivity only for the TSPY1 (multicopy target) assay. CONCLUSIONS: qPCR was not found to be an effective tool for RHD genotyping in suboptimal samples (<2% cffDNA). However, when testing the same suboptimal samples on the same day by dPCR, 100% sensitivity was achieved for both fetal sex determination and RHD genotyping. Use of dPCR for identification of fetal specific markers can reduce the occurrence of false-negative and inconclusive results, particularly when samples express high levels of background maternal cell-free DNA.
- 13 April 2015
- Published by Wiley in ISBT Science Series
- Vol. 10 (S1) , 250-256
Next‐generation sequencing: academic overkill or high‐resolution routine blood group genotyping?
Blood group genotyping (BGG) has been in routine clinical practice ever since the molecular determination of blood groups was achieved, during the early to mid 1990s. These early methods were dependent on allele‐specificPCRto detect simple single nucleotide polymorphisms (SNPs) responsible for blood group expression. As our knowledge regarding the molecular background of blood groups advanced, so did the numbers ofSNPs requiring detection which necessitated the switch from allele‐specificPCRto array‐based technology, notably slide and bead‐based approaches. All these methods thus described are totally dependent on the predefined genetic basis of eachSNP. Hybrid blood group genes (as found inRH,ABOandMNSsystems) are difficult to define by all of these aforementioned techniques. With the arrival of cheap next‐generation sequencing (NGS) approaches in the past 5 years, we have conducted long‐rangePCR(LR‐PCR) coupled withNGSdetermination of the major blood group genes. By analysis of these data using an Ion Torrent Personal Genome Machine™(PGM™), it is readily apparent thatNGScan highly effectively be applied with high resolution to blood grouping at costs no more than current array‐based platforms. However, the complexity of the data obtained need careful filtering for effective clinical utilization, but provides useful insight on the evolution of blood groups and their environmental impacts which will be of undoubted value as an academic exercise, but of minimal cost (if any) to the original testing.
- 13 April 2015
- Published by Wiley in ISBT Science Series
- Vol. 10 (S1) , 250-256
Next‐generation sequencing: academic overkill or high‐resolution routine blood group genotyping?
Blood group genotyping (BGG) has been in routine clinical practice ever since the molecular determination of blood groups was achieved, during the early to mid 1990s. These early methods were dependent on allele‐specificPCRto detect simple single nucleotide polymorphisms (SNPs) responsible for blood group expression. As our knowledge regarding the molecular background of blood groups advanced, so did the numbers ofSNPs requiring detection which necessitated the switch from allele‐specificPCRto array‐based technology, notably slide and bead‐based approaches. All these methods thus described are totally dependent on the predefined genetic basis of eachSNP. Hybrid blood group genes (as found inRH,ABOandMNSsystems) are difficult to define by all of these aforementioned techniques. With the arrival of cheap next‐generation sequencing (NGS) approaches in the past 5 years, we have conducted long‐rangePCR(LR‐PCR) coupled withNGSdetermination of the major blood group genes. By analysis of these data using an Ion Torrent Personal Genome Machine™(PGM™), it is readily apparent thatNGScan highly effectively be applied with high resolution to blood grouping at costs no more than current array‐based platforms. However, the complexity of the data obtained need careful filtering for effective clinical utilization, but provides useful insight on the evolution of blood groups and their environmental impacts which will be of undoubted value as an academic exercise, but of minimal cost (if any) to the original testing.
- 4 October 2013
- Published by Wiley in Transfusion
- Vol. 53 (10) , 2111
Glycophorin C ligation: another biochemical pathway in red blood cell senescence?
- 4 October 2013
- Published by Wiley in Transfusion
- Vol. 53 (10) , 2111
Glycophorin C ligation: another biochemical pathway in red blood cell senescence?
- Open Access
- 31 May 2013
- Published by MDPI AG in Diagnostics
- Vol. 3 (2) , 291-314
Non-Invasive Screening Tools for Down’s Syndrome: A Review
Down’s syndrome (DS) is the most common genetic cause of developmental delay with an incidence of 1 in 800 live births, and is the predominant reason why women choose to undergo invasive prenatal diagnosis. However, as invasive tests are associated with around a 1% risk of miscarriage new non-invasive tests have been long sought after. Recently, the most promising approach for non-invasive prenatal diagnosis (NIPD) has been provided by the introduction of next generation sequencing (NGS) technologies. The clinical application of NIPD for DS detection is not yet applicable, as large scale validation studies in low-risk pregnancies need to be completed. Currently, prenatal screening is still the first line test for the detection of fetal aneuploidy. Screening cannot diagnose DS, but developing a more advanced screening program can help to improve detection rates, and therefore reduce the number of women offered invasive tests. This article describes how the prenatal screening program has developed since the introduction of maternal age as the original “screening” test, and subsequently discusses recent advances in detecting new screening markers with reference to both proteomic and bioinformatic techniques.
- 31 May 2013
- Published by MDPI AG in Diagnostics
- Vol. 3 (2) , 291-314
Open AccessNon-Invasive Screening Tools for Down’s Syndrome: A Review
Down’s syndrome (DS) is the most common genetic cause of developmental delay with an incidence of 1 in 800 live births, and is the predominant reason why women choose to undergo invasive prenatal diagnosis. However, as invasive tests are associated with around a 1% risk of miscarriage new non-invasive tests have been long sought after. Recently, the most promising approach for non-invasive prenatal diagnosis (NIPD) has been provided by the introduction of next generation sequencing (NGS) technologies. The clinical application of NIPD for DS detection is not yet applicable, as large scale validation studies in low-risk pregnancies need to be completed. Currently, prenatal screening is still the first line test for the detection of fetal aneuploidy. Screening cannot diagnose DS, but developing a more advanced screening program can help to improve detection rates, and therefore reduce the number of women offered invasive tests. This article describes how the prenatal screening program has developed since the introduction of maternal age as the original “screening” test, and subsequently discusses recent advances in detecting new screening markers with reference to both proteomic and bioinformatic techniques.
- 1 January 2013
- Published by Portico in Drugs of Today
- Vol. 49 (2) , 145-52
Maternal plasma biomarkers for Down syndrome: Present and future.
Down syndrome is the most common cause of mental retardation and has an incidence of between 1:600 and 1:800 pregnancies. It is the condition for which prenatal diagnosis is requested the most and most developed countries have adopted a screening program based around maternal plasma/serum testing and ultrasound. Advances have been made recently to eliminate invasive testing for genetic diagnosis of this condition based on the analysis of free fetal DNA in maternal plasma. But, routine noninvasive prenatal diagnosis for trisomy 21 still appears to be years away. Screening based on assessment of various biomarkers present in maternal plasma represents a front-line test to assess the risk of the mother carrying an aneuploid fetus. Recent comparative proteomics techniques have resulted in studies that have assessed maternal plasma from mothers carrying normal and trisomy 21 fetuses and various gestational ages. Over 100 biomarker candidates have been described, but little consensus has emerged. This may be due to a number of compounded factors, but interesting to note that other neurological disorders have overlapping biomarkers. This article describes these developments and how these biomarkers could contribute to future screening in an emerging era where next-generation sequencing of free fetal DNA will be established in prenatal diagnostics, which appears imminent.
- 1 January 2013
- Published by Portico in Drugs of Today
- Vol. 49 (2) , 145-52
Maternal plasma biomarkers for Down syndrome: Present and future.
Down syndrome is the most common cause of mental retardation and has an incidence of between 1:600 and 1:800 pregnancies. It is the condition for which prenatal diagnosis is requested the most and most developed countries have adopted a screening program based around maternal plasma/serum testing and ultrasound. Advances have been made recently to eliminate invasive testing for genetic diagnosis of this condition based on the analysis of free fetal DNA in maternal plasma. But, routine noninvasive prenatal diagnosis for trisomy 21 still appears to be years away. Screening based on assessment of various biomarkers present in maternal plasma represents a front-line test to assess the risk of the mother carrying an aneuploid fetus. Recent comparative proteomics techniques have resulted in studies that have assessed maternal plasma from mothers carrying normal and trisomy 21 fetuses and various gestational ages. Over 100 biomarker candidates have been described, but little consensus has emerged. This may be due to a number of compounded factors, but interesting to note that other neurological disorders have overlapping biomarkers. This article describes these developments and how these biomarkers could contribute to future screening in an emerging era where next-generation sequencing of free fetal DNA will be established in prenatal diagnostics, which appears imminent.
- Open Access
- 1 December 2012
- Published by Walter de Gruyter GmbH in Balkan Journal of Medical Genetics
- Vol. 15 (Supplement) , 17-26
Non Invasive Prenatal Diagnosis of Aneuploidy: Next Generation Sequencing or Fetal DNA Enrichment?
Current invasive procedures [amniocentesis and chorionic villus sampling (CVS)] pose a risk to mother and fetus and such diagnostic procedures are available only to high risk pregnancies limiting aneuploidy detection rate. This review seeks to highlight the necessity of investing in non invasive prenatal diagnosis (NIPD) and how NIPD would improve patient safety and detection rate as well as allowing detection earlier in pregnancy. Non invasive prenatal diagnosis can take either a proteomics approach or nucleic acid-based approach; this review focuses on the latter. Since the discovery of cell free fetal DNA (cffDNA) and fetal RNA in maternal plasma, procedures have been developed for detection for monogenic traits and for some have become well established (e.g., RHD blood group status). However, NIPD of aneuploidies remains technically challenging. This review examines currently published literature evaluating techniques and approaches that have been suggested and developed for aneuploidy detection, highlighting their advantages and limitations and areas for further research.
- 1 December 2012
- Published by Walter de Gruyter GmbH in Balkan Journal of Medical Genetics
- Vol. 15 (Supplement) , 17-26
Open AccessNon Invasive Prenatal Diagnosis of Aneuploidy: Next Generation Sequencing or Fetal DNA Enrichment?
Current invasive procedures [amniocentesis and chorionic villus sampling (CVS)] pose a risk to mother and fetus and such diagnostic procedures are available only to high risk pregnancies limiting aneuploidy detection rate. This review seeks to highlight the necessity of investing in non invasive prenatal diagnosis (NIPD) and how NIPD would improve patient safety and detection rate as well as allowing detection earlier in pregnancy. Non invasive prenatal diagnosis can take either a proteomics approach or nucleic acid-based approach; this review focuses on the latter. Since the discovery of cell free fetal DNA (cffDNA) and fetal RNA in maternal plasma, procedures have been developed for detection for monogenic traits and for some have become well established (e.g., RHD blood group status). However, NIPD of aneuploidies remains technically challenging. This review examines currently published literature evaluating techniques and approaches that have been suggested and developed for aneuploidy detection, highlighting their advantages and limitations and areas for further research.
- 1 April 2012
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (4) , 657-658
Refining Noninvasive Prenatal Diagnosis with Single-Molecule Next-Generation Sequencing
The gradual elimination of risky procedures used to sample fetal material for prenatal diagnosis has been an important objective in medicine. It is often stated
- 1 April 2012
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (4) , 657-658
Refining Noninvasive Prenatal Diagnosis with Single-Molecule Next-Generation Sequencing
The gradual elimination of risky procedures used to sample fetal material for prenatal diagnosis has been an important objective in medicine. It is often stated
- Open Access
- 19 September 2011
- Published by Springer Nature in Proteome Science
- Vol. 9 (1) , 56
2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
Background: Prenatal screening for Down Syndrome (DS) would benefit from an increased number of biomarkers to improve sensitivity and specificity. Improving sensitivity and specificity would decrease the need for potentially risky invasive diagnostic procedures.Results: We have performed an in depth two-dimensional difference gel electrophoresis (2D DIGE) study to identify potential biomarkers. We have used maternal plasma samples obtained from first and second trimesters from mothers carrying DS affected fetuses compared with mothers carrying normal fetuses. Plasma samples were albumin/IgG depleted and expanded pH ranges of pH 4.5 - 5.5, pH 5.3 - 6.5 and pH 6 - 9 were used for two-dimensional gel electrophoresis (2DE). We found no differentially expressed proteins in the first trimester between the two groups. Significant up-regulation of ceruloplasmin, inter-alpha-trypsin inhibitor heavy chain H4, complement proteins C1s subcomponent, C4-A, C5, and C9 and kininogen 1 were detected in the second trimester in maternal plasma samples where a DS affected fetus was being carried. However, ceruloplasmin could not be confirmed as being consistently up-regulated in DS affected pregnancies by Western blotting.Conclusions: Despite the in depth 2DE approach used in this study the results underline the deficiencies of gel-based proteomics for detection of plasma biomarkers. Gel-free approaches may be more productive to increase the number of plasma biomarkers for DS for non-invasive prenatal screening and diagnosis.
- 19 September 2011
- Published by Springer Nature in Proteome Science
- Vol. 9 (1) , 56
Open Access2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
Background: Prenatal screening for Down Syndrome (DS) would benefit from an increased number of biomarkers to improve sensitivity and specificity. Improving sensitivity and specificity would decrease the need for potentially risky invasive diagnostic procedures.Results: We have performed an in depth two-dimensional difference gel electrophoresis (2D DIGE) study to identify potential biomarkers. We have used maternal plasma samples obtained from first and second trimesters from mothers carrying DS affected fetuses compared with mothers carrying normal fetuses. Plasma samples were albumin/IgG depleted and expanded pH ranges of pH 4.5 - 5.5, pH 5.3 - 6.5 and pH 6 - 9 were used for two-dimensional gel electrophoresis (2DE). We found no differentially expressed proteins in the first trimester between the two groups. Significant up-regulation of ceruloplasmin, inter-alpha-trypsin inhibitor heavy chain H4, complement proteins C1s subcomponent, C4-A, C5, and C9 and kininogen 1 were detected in the second trimester in maternal plasma samples where a DS affected fetus was being carried. However, ceruloplasmin could not be confirmed as being consistently up-regulated in DS affected pregnancies by Western blotting.Conclusions: Despite the in depth 2DE approach used in this study the results underline the deficiencies of gel-based proteomics for detection of plasma biomarkers. Gel-free approaches may be more productive to increase the number of plasma biomarkers for DS for non-invasive prenatal screening and diagnosis.
- 1 December 2009
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 2 (6) , 641-643
Transfusion medicine education session
The European Haematology Association annual meeting is the second largest conference organized specifically for hematologists. This meeting report gives an overview of one particular session within this meeting, that of the transfusion medicine subject speciality, which included two speakers from the USA and one from the UK. The following lectures will be reviewed here: Jo-Ann Moulds--Transfusion policies and practices in alloimmunized sickle cell patients; Derwood Pamphilon--Transfusion problems in stem cell transplant patients; and Naomi Luban--Transfusion issues in neonatal and pediatric hematology. The session, therefore, included a significant discourse in clinical practice of transfusing the difficult to transfuse patient.
- 1 December 2009
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 2 (6) , 641-643
Transfusion medicine education session
The European Haematology Association annual meeting is the second largest conference organized specifically for hematologists. This meeting report gives an overview of one particular session within this meeting, that of the transfusion medicine subject speciality, which included two speakers from the USA and one from the UK. The following lectures will be reviewed here: Jo-Ann Moulds--Transfusion policies and practices in alloimmunized sickle cell patients; Derwood Pamphilon--Transfusion problems in stem cell transplant patients; and Naomi Luban--Transfusion issues in neonatal and pediatric hematology. The session, therefore, included a significant discourse in clinical practice of transfusing the difficult to transfuse patient.